UNSPSC 51182008: Fluoxymesterone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C20H29FO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JU12S4YFY, chemically known as 11-beta,17-beta-dihydroxy-9-alpha-fluoro-17-alpha-methyl-4-androster-3-one but generally known as fluoxymesterone, which bears US NIH Compound Identifier 6446. European Medicines Agency schedules Fluoxymesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07724MIG.

UNSPSC 51182008 Fluoxymesterone is a Commodity code representing specific pharmaceutical products that state and local health systems and facilities procure through multistate cooperative purchasing agreements. The code encompasses branded and generic formulations of fluoxymesterone, an anabolic steroid used in clinical settings, sourced through established pharmaceutical distribution networks and supplied to state agencies, counties, municipalities, and health departments that operate clinics, correctional facilities, and other treatment settings. State and local procurement under this code typically flows through multistate cooperative purchasing vehicles rather than individual jurisdiction RFPs, reducing administrative burden and consolidating purchasing power across member states and localities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation requires manufacturers to provide pricing for identified pharmaceutical products with specific National Drug Codes, maintain compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and work through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Awards take effect July 1, 2026, with a two-year initial term and optional extensions, and evaluation weighted heavily toward price competitiveness (75 percent) alongside fixed pricing structure (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000, and face performance penalties ranging from $200 to $1,500 per violation.